Correction to: Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20 mg/5 mg/12.5 mg fixed-dose combination in hypertension: a profile of its use
Page 2, column 2, section “What is the clinical efficacy of OLM/AMT/HCT 20 mg/5 mg/12.5 mg?”, paragraph 1, lines 5–8: The following text, which previously read. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - June 8, 2018 Category: Drugs & Pharmacology Source Type: research
Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Abstract
Olmesartan medoxomil (OM) is an antihypertensive drug with poor water solubility and low oral bioavailability (28.6%). Accordingly, this study aimed to formulate and evaluate OM nanosuspension incorporated into oral fast-dissolving films (FDFs) for bioavailability enhancement. OM nanosuspension was prepared by antisolvent-precipitation-ultrasonication method and characterized regarding particle size (122.67 ± 5.03 nm), span value (1.40 ± 0.51), and zeta potential (- 46.56 ± 1.20 mV). Transmission electron microscopy (TEM) of the nanosuspension showed spherical non-aggregating na...
Source: AAPS PharmSciTech - April 26, 2018 Category: Drugs & Pharmacology Authors: Alsofany JM, Hamza MY, Abdelbary AA Tags: AAPS PharmSciTech Source Type: research
Case of photosensitivity after the administration of olmesartan medoxomil
The Journal of Dermatology, EarlyView. (Source: The Journal of Dermatology)
Source: The Journal of Dermatology - March 31, 2018 Category: Dermatology Source Type: research
Long ‐term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease
The Journal of Clinical Hypertension, EarlyView. (Source: The Journal of Clinical Hypertension)
Source: The Journal of Clinical Hypertension - March 4, 2018 Category: Cardiology Source Type: research
A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension
Background:
Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD).
Objective/methods:
We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed or AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed with an olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily titrated to 40/25 mg if needed in a randomized, double-blind, 8-week study of 1085 participants with clinic SBP 160–190 mmHg and DBP 119 mmHg or less. Titration to higher doses occurred at week...
Source: Journal of Hypertension - March 1, 2018 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research
Identification and characterization of the druggable kinase targets of olmesartan and its analogues from a systematic kinase –chemical interaction profile in atherosclerosis
Publication date: March 2018 Source:Journal of Molecular Graphics and Modelling, Volume 80 Author(s): Rui-Juan Zhuang, Wei-Dong Jin, Xiao-Yan Wang, Xue-Ming Wu Olmesartan (OL) is the pharmacologically active metabolite of Olmesartan medoxomil (OM), an FDA-approved angiotensin II receptor antagonist for administrating cardiovascular diseases. The drug has been found to have potential effects on diverse protein kinase signaling involved in the pathogenesis of atherosclerosis, either by directly inhibiting the hub kinases or by indirectly modulating marginal members in the signaling pathways. In the present study, we co...
Source: Journal of Molecular Graphics and Modelling - March 1, 2018 Category: Molecular Biology Source Type: research
Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension
Publication date: 1 May 2018 Source:Colloids and Surfaces B: Biointerfaces, Volume 165 Author(s): Nilima T. Pandya, Parva Jani, Jigar Vanza, Hemal Tandel The aim of the current investigation was to develop solid lipid nanoparticles of olmesartan medoxomil using hot homogenization method to improve its oral bioavailability. Central composite design was applied to optimize the formulation variables; lipid X1 (Glyceryl monostearate) and surfactant X2 (Poloxamer: Tween 80). The particle sizes were in the nanometer range and spherical shaped for all prepared solid lipid nanoparticles formulations and the zeta potential ab...
Source: Colloids and Surfaces B: Biointerfaces - February 23, 2018 Category: Biochemistry Source Type: research
Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients
The efficacy and safety of olmesartan medoxomil (OM) vs active control (AC) monotherapy among elderly patients aged 60‐79 years (N = 4487) was evaluated by meta‐analysis (25 studies). In all patients, change from baseline to end point in blood pressure (BP) was significantly greater with OM vs AC (−19.5/−11.9 vs −16.8/−10.7 mm Hg). Greater proportions of OM‐ vs AC‐treated patients achieved BP goals. In patients with impaired renal function (estimated glomerular filtration rate <60 mL/min/1.73 m2), OM treatment resulted in a greater mean change from baseline in systolic BP vs AC (−21.2 vs −18.7...
Source: The Journal of Clinical Hypertension - February 20, 2018 Category: Cardiology Authors: Josep Redon, Michael A. Weber, Paul ‐Egbert Reimitz, Ji‐Guang Wang Tags: ORIGINAL PAPER Source Type: research
Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension.
Abstract
The aim of the current investigation was to develop solid lipid nanoparticles of olmesartan medoxomil using hot homogenization method to improve its oral bioavailability. Central composite design was applied to optimize the formulation variables; lipid X1 (Glyceryl monostearate) and surfactant X2 (Poloxamer: Tween 80). The particle sizes were in the nanometer range and spherical shaped for all prepared solid lipid nanoparticles formulations and the zeta potential absolute values were high, predicting good long-term stability. In vitro study of olmesartan loaded solid lipid nanoparticle exhibited c...
Source: Colloids and Surfaces - February 9, 2018 Category: Biotechnology Authors: Pandya NT, Jani P, Vanza J, Tandel H Tags: Colloids Surf B Biointerfaces Source Type: research
Long ‐term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease
An open‐label, long‐term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL‐M/CLD 20/12.5 mg (n = 77) or OLM/HCTZ 20/12.5 mg (n = 76), but could be up‐titrated (AZL‐M/CLD to 40/25 mg; OLM/HCTZ to 40/25 mg [US] or 20/25 mg [Europe]) with other agents added during weeks 4‐52. Primary endpoint was proportion of participants with ≥ 1 adverse event (AE) through week 52. Baseline demographics were similar. AEs did not differ betwe...
Source: The Journal of Clinical Hypertension - February 1, 2018 Category: Cardiology Authors: George L. Bakris, Lin Zhao, Stuart Kupfer, Attila Juhasz, Michie Hisada, Eric Lloyd, Suzanne Oparil Tags: ORIGINAL PAPER Source Type: research
In Brief: Olmesartan and Sprue-Like Enteropathy
Date: January 29, 2018
Issue #:
1539Summary:
A reader asked whether healthcare providers should avoid prescribing the angiotensin receptor blocker (ARB) olmesartan medoxomil (Benicar, and others) because it can cause severe GI adverse effects.In 2013, the FDA warned that olmesartan can cause sprue-like enteropathy, a condition characterized by intestinal villous atrophy, severe chronic diarrhea, and significant unintended weight loss. The warning was based on 23 cases of serious sprue-like enteropathy associated with use of olmesartan, some occurring years after starting the drug...
Source: The Medical Letter - December 27, 2017 Category: Drugs & Pharmacology Authors: admin Source Type: research
Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20 mg/5 mg/12.5 mg fixed-dose combination in hypertension: a profile of its use
AbstractThe triple-component fixed-dose combination of olmesartan medoxomil (OLM)/amlodipine (AML)/hydrochlorothiazide (HCT) is a rational choice for patients who require treatment with three or more antihypertensives. The three drugs in the FDC have complementary mechanisms of action, with OLM, AML and HCT being an angiotensin II receptor blocker, calcium channel blocker and diuretic, respectively. Once-daily OLM/AML/HCT 20 mg/5 mg/12.5 mg reduced systolic and diastolic blood pressure, thereby enabling patients to achieve blood pressure goals, and was generally well tolerated in clinical trials. Moreover, the use of a...
Source: Drugs and Therapy Perspectives - December 4, 2017 Category: Drugs & Pharmacology Source Type: research
The Effect of Ethanol on the Hydrolysis of Ester-type Drugs by Human Serum Albumin.
Abstract
Human serum albumin (HSA) has two major ligand-binding sites, sites I and II, and hydrolyzes compounds at both sites. Although the hydrolytic interaction of ester-type drugs with other drugs by HSA has been reported, there are only a few studies concerning the effect of pharmaceutical excipients on the hydrolysis of ester-type drugs by HSA. In the present study, we investigated the effect of ethanol (2 vol%; 345 mM) on the hydrolysis of aspirin, p-nitrophenyl acetate, and olmesartan medoxomil, which are ester-type drugs, with 4 different lots of HSA preparations. The hydrolysis activities of HSA t...
Source: Biological and Pharmaceutical Bulletin - November 27, 2017 Category: Drugs & Pharmacology Authors: Tatsumi A, Inoue S, Hamaguchi T, Iwakawa S Tags: Biol Pharm Bull Source Type: research
A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan.
We report a case of sprue-like enteropathy associated with telmisartan. A 52-year-old man presented with chronic diarrhea, abdominal discomfort and significant weight loss. In the last 3 years, he had been treated with telmisartan 40 mg/day for hypertension after right adrenalectomy for an aldosterone-producing adenoma. Laboratory investigations showed no significant abnormalities: Hb 13.6 g/dL, serum albumin 3.9 g/dL, total cholesterol 193 mg/dL, serum creatinine 0.99 mg/dL, sodium 143.6 mmol/L, K(+) 4.3 mmol/L, calcium 9.3 mg/dL, phosphorus 3.9 mg/dL and 25-OH-D3 27.7 ng/mL. Duodenal histology showed subtotal VA and infl...
Source: Clin Med Res - November 24, 2017 Category: Research Authors: Negro A, De Marco L, Cesario V, Santi R, Boni MC, Zanelli M Tags: J Clin Med Res Source Type: research
Olmesartan ‐based monotherapy vs combination therapy in hypertension: A meta‐analysis based on age and chronic kidney disease status
Antihypertensive monotherapy is often insufficient to control blood pressure (BP). Several recent guidelines advocate for initial combination drug therapy in many patients. This meta‐analysis of seven randomized, double‐blind studies (N = 5888) evaluated 8 weeks of olmesartan medoxomil (OM)–based single‐pill dual‐combination therapy (OM+amlodipine/azelnidipine or hydrochlorothiazide) vs OM monotherapy in adults with hypertension. BP‐lowering efficacy, goal achievement, and adverse events were assessed in the full cohort and subgroups (elderly/nonelderly and patients with and without chronic kidney disease). ...
Source: The Journal of Clinical Hypertension - October 25, 2017 Category: Cardiology Authors: Prakash Deedwania, Michael Weber, Paul ‐Egbert Reimitz, George Bakris Tags: ORIGINAL PAPER Source Type: research
